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Cilengitide (EMD121974), an inhibitor of the adhesive function of integrins, demonstrated preclinical efficacy against
malignant glioma. It is speculated that cilengitide can inhibit tumor growth, invasion, and angiogenesis. However,
the effects of cilengitide on these processes have not been sufficiently examined. In this study, we investigated the
anti-glioma effect of cilengitide using DNA microarray analysis. U87ΔEGFR cells (human malignant glioma cell line)
were used for this experiment. The cells were harvested after 16 h of cilengitide treatment, and mRNA was
extracted. Gene expression and pathway analyses were performed using a DNA microarray (CodeLink™ Human
Whole Genome Bioarray). The expression of 265 genes was changed with cilengitide treatment. The expression of
214 genes was up-regulated by more than 4-fold and the expression of 51 genes was down-regulated by more
than 4-fold compared to the controls. In pathway analysis, “apoptotic cleavage of cellular proteins” and “TNF
receptor signaling pathway” were over-represented. Apoptotic-associated genes such as caspase 8 were up-
regulated. Gene expression profiling revealed more detailed mechanism of the anti-glioma effect of cilengitide.
Genes associated with apoptosis were over-represented following cilengitide treatment.
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Gliomas are the most frequent primary intracranial neo-
plasm in adults and are invariably fatal. The median sur-
vival of aggressively treated patients with glioblastoma is
approximately 14.6 months (Stupp & Weber 2005). The
resistance of gliomas to the conventional therapeutic
regimen of surgery, radiotherapy, and chemotherapy has
prompted many investigators to seek novel therapeutic
approaches for this fatal disease (Chatterjee et al. 2000).
Moreover, alterations of the epidermal growth factor re-
ceptor (EGFR) gene are common in some forms of can-
cer and the most frequent is a deletion of exons 2–7. It
was previously reported that this mutant receptor, called
ΔEGFR, confers enhanced tumorigenicity on glioblast-
oma cells through elevated proliferation and reduced
apoptotic rates in vivo (Narita et al. 2002).* Correspondence: kkuro@md.okayama-u.ac.jp
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in any medium, provided the original work is pIntegrins control the attachment of cells to the extra-
cellular matrix (ECM) and participate in cellular defense
against genotoxic assaults (Hynes 2002). Integrins are
expressed in tumor cells and tumor endothelial cells
(Varner & Cheresh 1996a; Varner & Cheresh 1996b;
Varner et al. 1995), and they play important roles in
angiogenesis and invasion in glioma (Friedlander et al.
1995; Brooks et al. 1994a; Brooks et al. 1994b). αvβ3
and αvβ5 integrins regulate cell adhesion (Hodivala-
Dilke et al. 2003; Leavesley et al. 1992), and inhibitors of
these integrins suppress tumor growth in certain pre-
clinical models (MacDonald et al. 2001). Therefore,
integrins have attracted attention as potential thera-
peutic targets in glioma.
Currently, αvβ3 and αvβ5 integrin antagonists includ-
ing cilengitide (EMD121974), which is a cyclic RGD-
containing peptide (Xiong et al. 2001), are in clinical
trials. This drug is reportedly able to penetrate the
blood brain barrier (BBB) in vivo (Nabors et al. 2007).
Cilengitide induces anoikis in angiogenic blood vessels
and brain tumor cells in vitro (Oliveira-Ferrer et al.
2008; Alghisi et al. 2009); however, the mechanismsn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Onishi et al. SpringerPlus 2013, 2:160 Page 2 of 11
http://www.springerplus.com/content/2/1/160underlying its cytotoxic effects are not completely
understood.
There have been no microarray studies to date that ex-
amined the changes in gene expression after cilengitide
treatment. U87ΔEGFR cells were previously shown to
have increased tumorigenicity via elevated proliferation
and reduced apoptosis compared to U87 cells, which
cause a more aggressive phenotype than that of the
parental cell line (Narita et al. 2002). In this study, we
profiled and examined the gene expression of over
57000 genes using the most comprehensive GeneChip
microarrays available (CodeLink™ Human Whole Gen-
ome Bioarray), and identified differentially expressed
genes between untreated glioma cells (U87ΔEGFR) and
cilengitide-treated glioma cells to reveal more detail
mechanism of anti-glioma effect of cilengitide.
Materials and methods
Glioma cell line and drug
Glioma cell lines, U87ΔEGFR, were seeded in tissue
culture dishes (BD Falcon, Franklin Lakes, NJ, USA)
and cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U penicillin, and 0.1 mg/mL streptomycin.
U87MG, Gli36Δ5, and U251 human glioma cells were
also prepared and maintained as described previously
(Kambara et al. 2005). Cilengitide was generously pro-
vided by Merck KgaA and the National Cancer Institute,
National Institutes of Health.
Cell surface immunofluorescence assay
U87ΔEGFR cells were seeded on 4 Chamber Polystyrene
Vessel Tissue Culture Treated Glass Slides (BD Falcon,
Franklin Lakes, NJ, USA) and incubated overnight. For
immunofluorescence, the cells were fixed in 4% parafor-
maldehyde in phosphate-buffered saline (PBS) for 15 min.
After the cells were fixed, they were rinsed 3 times with
PBS. Nonspecific binding was blocked by incubation in a
blocking buffer containing 2% bovine serum albumin in
PBS for 30 min at room temperature. The cells were
incubated overnight at 4°C with a mouse anti-human
integrin αvβ3 monoclonal antibody (Millipore Corpor-
ation, Billerica, MA, USA) or mouse anti-human integ-
rin αvβ5 monoclonal antibody (Abcam, Cambridge, UK)
diluted 1:100 in blocking buffer. The cells were washed
3 times in blocking buffer for 5 min before incubation
with a secondary anti-mouse CY3-conjugated antibody
(Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA) diluted 1:300 in blocking buffer for 2 h
at room temperature in the dark. After 3 washes in PBS,
the cells were counterstained with 40, 6-diamino-2-
phenylindole (DAPI; 1:500) (Invitrogen, Carlsbad, CA,
USA) (100 ng/mL) for 20 min at room temperature.
The slides were washed 3 times in PBS and mounted.Water-soluble tetrazolium-1 assay
A water-soluble tetrazolium (WST)-1 assay (Roche Diag-
nostics) was performed according to the manufacturer’s
instructions. Briefly, cells treated with saline (control
cells) or Cilengitide (1.0 μM) (Cilengitide was generously
provided by Merck KGaA and the National Cancer Insti-
tute, NIH) were plated in a 96-well plate at a concentra-
tion of 25,000 cells/mL. Cell survival was measured at
the indicated time points by adding 10 μL of a 1:3 (v/v)
diluted ready-to-use WST-1 cell proliferation reagent
stock solution (Roche, Mannheim). The samples were
incubated for 60–240 min and absorption was measured
with an MTP-120 micro plate reader (CORONA ELEC-
TRIC Co., Ibaragi, Japan) at 450 nm wavelength using a
620 nm reference filter. After subtraction of the back-
ground absorption, the mean value of the untreated con-
trol cells was set as 100%.
Microarray analysis
U87ΔEGFR cells treated with cilengitide (1.0 μM for
16 h) and untreated control U87ΔEGFR cells were
analyzed using a CodeLink™ Human Whole Genome
Bioarray (Applied Microarrays, Inc., Tempe, AZ, USA).
We entrusted the microarray analyses to Filgen, Inc.
(Nagoya, Japan). Briefly, for each bioarray, 10 μg of
cRNA in a 25 μL total volume were added to 5 μL of 5×
fragmentation buffer, which was then incubated at 94°C
for 20 min. Thereafter, 10 μg of fragmented cRNA, 78 μL
of hybridization buffer component A, and 130 μL of
hybridization buffer component B were added, and the
final volume was brought up to 260 μL with water. The
resultant hybridization reaction mixture was incubated at
90°C for 5 min, after which 250 μL were slowly injected
into the input port of each array, and the ports were sealed
with sealing strips. The bioarrays were then incubated for
18 h at 37°C while shaking at 300 rpm. A consistent
hybridization time was maintained for comparative exper-
iments. Following the incubation, the bioarrays were
washed with 0.75 TNT buffer (0.10 M Tris–HCl, pH 7.6,
0.15 M NaCl, 0.05% Tween 20) and incubated at 46°C for
1 h. Each slot of the small reagent reservoir was then filled
with 3.4 mL of Cy5-Streptavidin working solution, and the
array was incubated at 25°C for another 30 min. Thereafter,
the bioarrays were washed 4 times for 5 min each with 1 ×
TNT buffer at 25°C, rinsed twice in 0.1× SSC (Ambion,
Austin, TX, USA)/0.05% Tween 20 for 30 s each, and im-
mediately dried by centrifugation for 3 min at 25°C. Finally,
the arrays were scanned using a GenePix4000B Array
Scanner (Molecular Devices, Sunnyvale, CA, USA). A gene
was defined as being upregulated when the cilengitide
treatment/control average intensity ratio was >4.0, and
downregulated when the cilengitide treatment/control
ratio was <0.25. We performed pathway analysis on the
genes that expressed increase and decrease using
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data were extracted using the following criteria: Z-
score > 0 and P-value < 0.05 (Ichii et al. 2011; Yoshino
et al. 2011).
Quantitative reverse-transcription polymerase chain
reaction (QRT-PCR)
Total RNA was isolated from cultured U87ΔEGFR cells
treated with cilengitide (1.0 μM for 16 h) and untreated
control U87ΔEGFR cells using an RNeasyW Mini Kit
(QIAGEN, Hilden, Germany). In vivo, that RNA was
extracted from the brain tumor tissue of rat that had
been treated with PBS or with Cilengitide with the use
of TRIZOL reagent (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. Those
RNA were reverse transcribed with oligo dT primers
using the SuperScript III First-Strand Synthesis System
for RT-PCR (Invitrogen, Carlsbad, CA, USA) according
to manufacturer’s instructions. Primers specific for each
gene were designed using Primer 3 Plus Software (http://
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi)
and synthesized by Invitrogen. The resulting cDNA was
amplified by PCR using gene-specific primers and the 7300
Real Time PCR system (Applied Biosystems, Foster City,
CA, USA) and QuantiTectTM SYBRW Green PCR Kit
(QIAGEN, Hilden, Germany). A log-linear relationship be-
tween the amplification curve and quantity of cDNA in the
range of 1–1000 copies was observed. The cycle number at
the threshold was used as the threshold cycle (Ct). The
different expression of mRNA was detected from 2-ΔΔCt
using the 7300 Real Time PCR System with Sequence
Detection Software (version 1.4; Applied Biosystems,
Foster City, CA, USA). The amount of cDNA in each
sample was normalized to the crossing point of the
housekeeping gene glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH). The following thermal cycling
parameters were used: denaturation at 95°C for 10 min
followed by 45 cycles at 94°C for 15 s, 50°C for 30 s, and
72°C for 30 s. The relative mRNA upregulation for each
gene in the control was calculated using their respective
crossing points with the following formula, as previ-
ously described (Kurozumi et al. 2007):
F = 2(TH − TG) − (OH − OG) where, F = fold difference, T =
control, O = treated cell or tumor, H = housekeeping
(GAPDH), and G = gene of interest.
CASPASE 8 primers
CASP8 F (forward), 5-TGCAGGGTCTCACTCTGTTG-3
CASP8 R (reverse), 5-TTGATTTTGGAGGGATCTCG-3
protein kinase C, zeta primers
PKCZ F (forward), 5-GTTATCGATGGGATGGATGG-3
PKCZ R (reverse), 5-GCACCAGCTCTTTCTTCACC-3
GAPDH primers
GAPDH F (forward), 5- GAGTCAACGGATTTGGTCGT-3
GAPDH R (reverse), 5-TTGATTTTGGAGGGATCTCG-3Activity assay of caspase-3/7 and -8
Caspase-3/7 and -8 activity levels were measured using
CellEvent™ Caspase-3/7 Green Detection Reagent (Invi-
trogen, Carlsbad, CA, USA) and the colorimetric protease
assay kit (MBL, CA, USA), respectively, according to the
protocol recommended by the manufacturer. Briefly, cells
(5,000 cells per well) were plated in 96-well plates in tripli-
cate and treated with cilengitide. Cilengitide (1.0 μM) was
added to the medium after 24 h of incubation. The
caspase solution was added at 16 h after adding cilengitide.
After incubation with these substrates, the absorbance of
each well was measured using a microplate reader.
TdT-mediated dUTP nick end labeling (TUNEL) assay
U87ΔEGFR cells were seeded in 6-well plates (1.0 × 104
cells/well) and cultured in DMEM supplemented with
10% FBS. Cilengitide (10 μM) was added to the medium
after 24 h of incubation. After incubation for 16 h at
37°C, the cells were examined for morphological
changes. Apoptotic cells were detected with the In Situ
Cell Death Detection Kit (Roche, Basel, Switzerland)
according to the manufacturer’s instructions.
Immunoblot analysis
Using immunoblot analysis, we examined whether treat-
ment with cilengitide induced caspase activation via
caspase 8 and caspase 3. Western blotting was carried
out at a high stringency, essentially as described previ-
ously (Kurozumi et al. 2004; Michiue et al. 2005a; Michiue
et al. 2005b). The harvested cells with treated each con-
centration of drug (0.1, 1.0, 10 μM: 16 hr) or each time
course (8, 16, 24 hr: 1 μM) were lysed by a sonicator in a
boiled buffer containing 1% SDS. The cell lysate (50 μg)
was subjected to SDS-PAGE and transferred to nitrocellu-
lose membranes (Hybond ECL, GE Healthcare UK Ltd,
England). The blots were probed with each primary anti-
body. Specific bands were visualized with an enhanced
chemiluminescence detection kit (GE Healthcare UK Ltd,
England). The following primary rabbit polyclonal anti-
bodies were used: anti-human caspase 8 (1:500; ab44976,
abcam, Inc., UK), anti-human caspase 3 (1:250; ab32125,
abcam, Inc., UK), and β-actin (1:1000; Sigma-Aldrich, St.
Louis, MO, USA).
Brain xenografts
All experimental animals were housed and handled in
accordance with the guidelines of the Okayama Univer-
sity Animal Research Committee. Before implantation,
85–90% confluent U87ΔEGFR cells were trypsinized,
rinsed with DMEM supplemented with 10% FBS, and
centrifuged at 100 × g for 5 min; the resulting pellet was
resuspended in PBS, and the cell concentration was ad-
justed to 1.0 × 105 cells/μL. U87ΔEGFR cells (5 μL) were
injected into athymic rats (F344/N-nu/nu; CLEA Japan,
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placed in stereotactic frames (Narishige, Tokyo, Japan)
with their skulls exposed. Tumor cells were injected with
a Hamilton syringe (Hamilton, Reno, NV, USA) into the
right frontal lobe (4 mm lateral and 1 mm anterior to
the bregma at a depth of 4 mm) and the syringe was
slowly withdrawn after 5 min to prevent reflux. The skulls
were then cleaned, the holes were sealed with bone wax,
and the incision was sutured. Cilengitide or PBS was ad-
ministered 3 times/week intraperitoneally (1 mg/500 μL
PBS), starting on day 5 after tumor cell implantation. To
assess the gene expression of caspase 8 with QRT-PCR,
athymic rats harboring U87ΔEGFR brain tumors were
sacrificed at 18 days after tumor implantation. The tumor-
bearing right hemispheres of the brains were excised and
processed for RNA. For measurements of tumor cell
apoptosis, athymic rats were sacrificed at 18 days after
tumor implantation. The brains were removed and fixed
in 4% paraformaldehyde for at least 24 h.
TUNEL staining in vivo
Snap-frozen tissue samples were embedded in optimal
cutting temperature solution (Sakura Finetek Inc., Tor-
rance, CA, USA) for cryosectioning, and 16-μm cryostat
sections were cut. Apoptotic tumor cells were detected
using the In Situ Cell Death Detection Kit (Roche, Basel,
Switzerland) according to the manufacturer’s instructions.
Statistical analysis
Student’s t test was used to test for statistical significance.
Data are presented as the mean ± standard error. All
statistical analyses were performed with the use of SPSS
statistical software (version 14.0; SPSS, Inc., Chicago, IL,
USA).
Results
Immunohistochemical analysis of αvβ3 and αvβ5
integrins expression in U87ΔEGFR cells
Immunofluorescence assays were conducted to determine
the expression of αvβ3 and αvβ5 integrins in U87ΔEGFR
cells. Cultured U87ΔEGFR cells were immunopositive for
αvβ3 and αvβ5 integrins (Figure 1a, b).
Cytotoxic effects of cilengitide on the U87ΔEGFR glioma
cell line in vitro
The direct effects of cilengitide were investigated on gli-
oma cells in vitro. U87ΔEGFR cells were incubated with
cilengitide at concentrations of 0–10 μM; 16 h later, the
cells were subjected to the WST-1 proliferation/viability
assay. Cell viability after 16 h of incubation was decreased
in cell cultures treated with cilengitide, reaching statistical
significance at 1 μM or higher (Figure 1c). In addition, cell
viability was decreased in cell cultures treated with 1 μM
cilengitide, reaching statistical significance at 16 h or later(Figure 1d). These cells became sensitive to cilengitide in
a concentration- and time-dependent manner.
Microarray analysis
Our cell viability assay showed that the decrease in the
number of viable cells treated with 1 μM cilengitide
reached statistical significance at 16 h. At that time point,
differential gene expression was compared between
cilengitide-treated U87ΔEGFR cells and untreated control
U87ΔEGFR cells (>4 fold change, <0.25 fold change)
(Figure 2a, b). There were 265 differentially expressed
genes between cilengitide-treated U87ΔEGFR cells and
control U87ΔEGFR cells with 214 upregulated and 51
downregulated. We further characterized the functional
significance of the dysregulated genes using pathway ana-
lysis. For the upregulated genes, 20 significantly enriched
pathways were identified for the differentially expressed
genes between cilengitide-treated U87ΔEGFR cells and
control cells (Table 1). For the downregulated genes, 7
significantly enriched pathways were identified (Table 2).
Especially for the upregulated genes, the significantly
enriched molecular pathways included apoptotic cleavage
of cellular proteins, FasL/CD95L signaling, TNF receptor
signaling pathway, and ceramide signaling pathway.
Caspase 8, desmoplakin, and protein kinase C, zeta were
included in these pathways and upregulated.
Validation of the microarray results
To confirm the reliability of the results from the micro-
array analysis, caspase 8, protein kinase C, zeta, were
verified by QRT-PCR analysis (Figure 3a, b). The relative
expression of caspase 8 and protein kinase C, zeta in
U87ΔEGFR cells incubated with cilengitide was signifi-
cantly higher than those of the cells without cilengitide
by 2.25-fold and 5.78-fold, respectively (P < 0.05).
Capsase activation assay and caspase expression in
western blotting
U87ΔEGFR cells were treated with 0.5 μM cilengitide
for 16 h. Cilengitide-induced caspase-8 activity was
detected with the colorimetric protease assay kit. The
relative absorbance (RA) of U87ΔEGFR cell clusters
were higher than control (0.27 ± 0.01 RA vs. 0.36 ± 0.01
RA, respectively; P < 0.05) (Figure 3a). U87ΔEGFR cells
were loaded with 8 μM CellEvent™ Caspase-3/7 Green
Detection Reagent then treated with the same concen-
tration. Cilengitide-induced caspase 3/7 activity was
detected with the CellEvent™ Caspase-3/7 Green Detec-
tion Reagent. The relative Fluorescence Unit (RFU)
of U87ΔEGFR cell clusters were higher than control
(35.4 ± 0.78 RFU vs. 16.5 ± 0.5 RFU, respectively;
P < 0.05) (Figure 3b). The next series of experiments was
designed to examine whether treatment with cilengitide
induced caspase activation in other cell lines. Caspase
Figure 1 Immunohistochemical analysis of the αvβ3 and αvβ5 integrins, and WST-1 proliferation/viability assay. Cultured U87ΔEGFR
cells were immunopositive for αvβ3 (a) and αvβ5 (b) integrins (Scale bar = 100 μm). Cilengitide reduced the number of viable cells in a dose and
time -dependent manner (*P < 0.05) (mean ± SE) (c, d).
Figure 2 Microarray and QRT-PCR analyses of cilengitide-treated cells. There were 265 differentially expressed genes between cilengitide-
treated U87ΔEGFR cells and untreated control U87ΔEGFR cells with 214 upregulated (a) and 51 downregulated (b) genes. Caspase-8 (c) and
protein kinase C, zeta (d) were significantly increased by cilengitide treatment (*P < 0.05) (mean ± SE, n = 3).
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Table 1 Significantly enriched pathways between cilengitide-treated U87ΔEGFR and control
Pathwayname Entrez gene ID Gene symbol P-value Z score
NF-kB activation through FADD/RIP-1 pathway
mediated by caspase-8 and -10
23586, 841 DDX58, CASP8 0.004 6.358
Organic cation/anion/zwitterion transport 55867, 6580 SLC22A11, SLC22A1 0.005 6.084
Cell adhesion molecules (CAMs) 1364, 4359, 941, :965 CLDN4, MPZ, CD80, CD58 0.014 3.213
NOSIP mediated eNOS trafficking 4846 NOS3 0.022 8.034
EPHB forward signaling 8867, 8997 SYNJ1, KALRN 0.026 3.585
Apoptotic cleavage of cellular proteins 1832, 841 DSP, CASP8 0.034 3.262
Regulation of RAC1 activity 2059, 8997 EPS8, KALRN 0.036 3.204
Activation, myristolyation of BID and translocation
to mitochondria
841 CASP8 0.037 5.593
Fatty acids 1580 CYP4B1 0.037 2.177
Signaling in Immune system 23586, 3429, 6196, 6672, :841,
84433, 941




LKB1 signaling events 2011, 57521 MARK2,RPTOR 0.037 2.631
ErbB1 downstream signaling 2059, 4086, 5590 EPS8, SMAD1, PRKCZ 0.039 4.964
FasL/CD95L signaling 841 CASP8 0.044 4.964
NOSTRIN mediated eNOS trafficking 4846 NOS3 0.044 4.964
Organic anion transport 55867 SLC22A11, 0.044 4.964
Pyrimidine biosynthesis 7372 UMPS 0.044 4.964
Release of eIF4E 57521 PRTOR 0.044 4.964
Ceramide signaling pathway 5590, 841 PRKCZ, CASP8 0.046 2.899
TNF receptor signaling pathway 5590, 841 PRKCZ, CASP8 0.046 2.899
Thromboxane A2 receptor signaling 4846, 5590 NOS3, PRKCZ 0.048 2.853
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Caspase 3 is produced as a 32-kDa proenzyme and
cleaved into its 17 kDa active form. In U251, Gli36Δ5,
U87MG, and U87ΔEGFR cells, cilengitide treatment in-
duced the activated form of caspase 3. Caspase 8 is pro-
duced as a 55-kDa proenzyme and cleaved into its
30 kDa and 15 kDa active form. In U251, Gli36Δ5,
U87MG, and U87ΔEGFR cells, cilengitide induced the
activated form of caspase 9. Immunoblot analysis re-
vealed that caspases 3 and 8 were processed in both cells
in response to cilengitide in a concentration- (Figure 3c)
and time-dependent manner (Figure 3d).Table 2 Downregulated pathway
Pathway name
Sphingolipid metabolism
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 membe
G alpha (s) signalling events
Syndecan-3-mediated signaling events
Sphingosine 1-phosphate (S1P) pathway
Signaling events mediated by the Hedgehog family
Pentose phosphate pathwayApoptosis analysis
To confirm the apoptosis of the deformed glioma cells
treated with cilengitide, the cells were stained with the
In Situ Cell Death Detection Kit using TMR red. Origin-
ally, U87ΔEGFR cells in culture were composed of
bipolar cells; however, they became spherical and aggluti-
nated when cilengitide was added to the culture medium.
Some of these deformed cells detached from the plate
(Figure 4a, b, c, d). These detached U87ΔEGFR cells were
not viable, as indicated by unsuccessful attempts of
re-plating these cells in medium that did not contain
cilengitide. U87ΔEGFR cell clusters were positive cellsEntrez gene ID Gene symbol P-value Z score
8879 SGPL1 0.006 16.049
rs 598 BCL2L1 0.015 8.496
134860, 4160 TAAR9, MC4R 0.022 3.717
4160 MC4R 0.032 5.52
8879 SGPL1 0.038 5.036
91653 BOC 0.042 4.771
8277 TKTL1 0.045 4.54
Figure 3 QRT-PCR analysis and activation of caspase-3/7 and -8 in cilengitide-treated cells. U87ΔEGFR cells were treated with 0.5 μM
cilengitide for 16 h with the colorimetric protease assay kit. For the activity of caspase-8, the relative absorbance (RA) of U87ΔEGFR cell clusters
were higher than control (0.27 ± 0.01 RA vs. 0.36 ± 0.01 RA, respectively; P < 0.05) (a). Cilengitide-induced apoptosis was also detected with the
CellEvent™ Caspase-3/7 Green Detection Reagent. The RFU of U87ΔEGFR cell clusters were higher than control (35.4 ± 0.78 RFU vs. 16.5 ± 0.5 RFU,
respectively; P < 0.05) (b). Immunoblot analysis revealed that caspases 3 and 8 were processed in all examined cell lines following treatment with
cilengitide in a concentration- (c) and time-dependent manner (d).
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ively; P < 0.05) (Figure 4e).
Cilengitide induces apoptosis in U87ΔEGFR-derived
xenografts
The effect of cilengitide on the induction of apoptosis was
examined in U87ΔEGFR-derived xenografts. At 5 days
after implantation, the rats were administered cilengitide
(1 mg/500 μL PBS) 3 times/week intraperitoneally, and the
rats were killed at 18 days after implantation. Caspase 8
gene expression was analyzed with QRT-PCR and the in-
duction of apoptosis in frozen sections of the U87ΔEGFR
xenografts was examined under a fluorescent microscope.
QRT-PCR revealed a statistically significant 10.1-fold in-
crease in caspase 8 gene expression in Cilengitide treated
tumors compared with control tumors (Figure 4f). A sub-
population of apoptotic cells were visualized by TUNEL
treatment using the In Situ Cell Death Detection Kit
(apoptotic cells: TMR red; nuclei: DAPI, blue). The
control sections exhibited a smaller amount of red
fluorescent cells (Figure 4g), whereas more scattered red
fluorescent cells were observed in the cilengitide-
treated xenografts (Figure 4h). To quantify the cytotoxic
effect of cilengitide, the number of apoptotic cells per
high-power field (HPF) in U87ΔEGFR control xeno-
grafts and U87ΔEGFR cilengitide-treated xenografts
were assessed (Figure 4i). The number of apoptotic cells
in U87ΔEGFR cilengitide-treated xenografts (26.2 ± 3.8
cells/HPF) was significantly higher than in U87ΔEGFRcontrol xenografts (1.40 ± 0.6 cells/HPF) (P < 0.05). The
average percentage of apoptotic cells was 5% in U87ΔEGFR
cilengitide-treated xenografts (Figure 4j).
Discussion
Cilengitide treatment induced morphological changes
and cell detachment in glioma cells incubated in dishes
and decreased cell viability in a dose and time-dependent
manner. Microarray analysis showed that the expression
of 265 genes was changed after cilengitide treatment. The
expression of 214 genes was up-regulated 4-fold more and
the expression of 51 genes was down-regulated to less
than 25% of control and apoptotic signaling pathways
were over-represented in the pathway analysis. In addition
to the effect of cilengitide in cultured cells, cilengitide also
induced apoptosis in U87ΔEGFR-derived xenografts,
suggesting that the induction of apoptosis also occurs
in vivo.
Cytotoxic effect of Cilengitide
Cilengitide is an angiogenesis inhibitor that targets the
integrins αvβ3 and αvβ5, which bind to ECM proteins
such as vitronectin and fibronectin (Burke et al. 2002;
Albert et al. 2006). Because integrins are expressed in
tumor cells and tumor endothelial cells (Varner &
Cheresh 1996a), it is speculated that cilengitide can inhibit
tumor growth by at least 2 mechanisms: by targeting the
tumor cells directly and by inhibiting tumor angiogenesis
(Tucker 2003; Oliveira-Ferrer et al. 2008; Chatterjee et al.
Figure 4 Nuclear DNA fragmentation in cilengitide-treated cells and in U87ΔEGFR-derived xenografts. To confirm the apoptosis of
deformed glioma cells treated with cilengitide, the cells were stained with the In Situ Cell Death Detection Kit using TMR red. U87ΔEGFR cells in
culture were composed of bipolar cells (a). They become spherical and agglutinated when cilengitide (1.0 μM) was added to their culture
medium. Some of these deformed cells detached from the plate (b). Untreated U87ΔEGFR cells were negative (c), whereas U87ΔEGFR cell
clusters treated with cilengitide were positive (d) (scale bar: 100 μm). The number of apoptotic cells in cilengitide-treated cells was significantly
larger than in control. (*P < 0.05) (e). QRT-PCR analysis of cilengitide-treated caspase 8 gene expression in tumors treated with PBS or cilengitide. *
P = .007 (f) (mean ± SE, n = 4) A subpopulation of apoptotic cells was visualized by TUNEL treatment (apoptotic cells: TMR red; nuclei: DAPI, blue)
of U87ΔEGFR control xenografts (g) and U87ΔEGFR cilengitide-treated xenografts (h) (Scale bar = 100 μm). The control sections exhibited
scattered red fluorescence, whereas more punctate red fluorescence was observed in the cilengitide-treated xenografts. To quantify the cytotoxic
effect of cilengitide, the number or percentage of apoptotic cells per high-power field (HPF) in U87ΔEGFR control xenografts and U87ΔEGFR
cilengitide-treated xenografts was assessed. The number (i) or percentage (j) of apoptotic cells in cilengitide-treated xenografts was significantly
larger than in control xenografts (*P < 0.05) (mean ± SE, n = 5).
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cilengitide as its direct effect on glioma cells (Onishi et al.
2012) And we also reported the multiple mechanism of
cilengitide for malignant glioma (Kurozumi et al. 2012).
Recent studies have shown that various cells are
dependent on integrin-mediated adhesion to specific ECM
proteins for their growth and survival and that detach-
ment induces a form of apoptotic cell death recognized as
anoikis (Chatterjee et al. 2000; Hynes 2002; Oliveira-
Ferrer et al. 2008; Alghisi et al. 2009). Other studies
reported that cilengitide exerts direct cytotoxic effects on
glioma cells via an as yet unknown mechanism (Mikkelsen
et al. 2009; Maurer et al. 2009; Oliveira-Ferrer et al. 2008).
In this study, we examined the mechanism of cilengitide-
induced cytotoxicity in glioma cells.Microarray analysis
U87ΔEGFR cells were chosen for gene chip analysis be-
cause they have a more aggressive phenotype than other
cell lines. ΔEGFR confers enhanced tumorigenicity on
glioblastoma cells through elevated proliferation and re-
duced apoptotic rates in vivo. It will be important and
interesting if we conduct a newly found cell death sig-
naling pathway via integrin stimulation in this aggressive
cell line.
Our data using the most sophisticated DNA micro-
array to date, profiling over 57000 genes, revealed the
mechanism underlying the anti-glioma effect of cilengitide.
After cilengitide treatment of glioma cells, apoptosis-
related genes (i.e., caspase 8, desmoplakin, and protein
kinase C, zeta) were upregulated. Apoptotic cleavage of
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naling pathway, and ceramide signaling pathway were in-
cluded in the significantly enriched molecular pathways.
Apoptosis is regulated by a series of biochemical events
that commit a cell to death. A common feature of cells
undergoing apoptosis is the activation of caspases, a family
of aspartic acid-directed proteases (Alnemri et al. 1996).
Caspases are activated during apoptosis and cleave specific
proteins, resulting in the irreversible commitment to cell
death. The signal transduction proteins MEKK1, p21-
activated kinase 2, and focal adhesion kinase are caspase
substrates that contribute to the cell death response when
cleaved.
FasL (CD95L) is a tumor necrosis factor (TNF)-related
type II membrane protein (Suda et al. 1993). Fas (CD95)
is a cell surface protein belonging to the TNF receptor
superfamily, and is expressed in glioma cells (Husain
et al. 1998). The binding of FasL to Fas induces the
trimerization of Fas, and FADD (Fas associated via DD
(death domain))/MORT1 binds to the trimerized FAS
cytoplasmic region through the interaction of their re-
spective DDs. Caspase-8 is then recruited to FADD/
MORT1 through binding of the DED (dead effector do-
main) domains, which in turn may induce the self-
activation of the protease domain (Nagata 1997).
TNF-R1-bound TRADD (TNF-receptor associated via
DD) recruits FADD through DD interaction. In turn,
FADD recruits procaspase-8 or -10, which are activated by
proximity, via its DED. Protein kinase C, zeta, is also in-
volved in the TNF receptor signaling pathway. Activation of
caspase-8 and -10 is sufficient to initiate a signaling cascade
that induces apoptosis (Schneider-Brachert et al. 2004).
Recently, similar changes in human umbilical vein endo-
thelial cells (HUVECs) have been reported for S 36578-2,
a novel RGD mimetic that selectively activates the αvβ3
and αvβ5 integrins(Maubant et al. 2006). This compound
induces cell detachment and apoptosis by the direct acti-
vation of caspase-8. Aoudjit and Vuori (Aoudjit & Vuori
2001) reported that detachment-induced cell death in
HUVECs resulted from the activation of the Fas pathway
by FasL/Fas interaction, Fas-FADD complex formation,
and caspase-8 activation. Previous reports on epithelial
cells also documented the involvement of FADD and
caspase-8 in detachment-induced apoptosis (Alghisi et al.
2009; Hynes 2002). Using human glioma cell lines ex-
pressing the αvβ3 and αvβ5 integrins, cilengitide caused a
profound detachment and increase of apoptosis in glioma
cells similar to what was observed in endothelial cells,
suggesting that identical mechanisms might occur in both
cell types (Oliveira-Ferrer et al. 2008).
Clinical application of cilengitide for malignant glioma
There have been several reports on the preliminary re-
sults of phase I and II trials of cilengitide for recurrentor newly diagnosed malignant glioma. Cilengitide mono-
therapy or combination treatment with radiation and/or
temozolomide is well tolerated and exhibits modest
antitumor activity (Reardon et al. 2008a; Reardon et al.
2008b; Nabors et al. 2012). According to our results, in
addition to the anti-angiogenic and anti-invasion effects
of cilengitide(Kurozumi et al. 2012; Onishi et al. 2012),
the cytotoxic effect of cilengitide was clearly shown.
cilengitide inhibited integrin binding and activated
caspase-8. This caspase-8 activation effect of cilengitide
would enhance the effect of other cytotoxic therapies.
Several preclinical studies have shown an enhanced
antitumor effect of cilengitide when administered in
combinatorial therapeutic regimens (Burke et al. 2002;
Abdollahi et al. 2005; Tentori et al. 2008; Reardon et al.
2008a). Mikkelsen et al. demonstrated that cilengitide
dramatically amplified the efficacy of radiation therapy
in an animal glioma model (Mikkelsen et al. 2009).
Kurozumi et al. demonstrated the enhanced therapeutic
efficacy of an oncolytic virus on experimental glioma
following pretreatment with cilengitide (Kurozumi et al.
2007).
Conclusion
We showed the cytotoxic effect of cilengitide on glioma
cells. Microarray analysis revealed the detailed mechan-
ism of the cytotoxic effect of cilengitide. Cilengitide, an
inhibitor of integrins, activated caspase-8 and induced
apoptosis-related pathways.
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